• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Optimization of cancer therapeutic strategies that target tankyrase-specific PARylation

Research Project

Project/Area Number 19H03523
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

SEIMIYA Hiroyuki  公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 部長 (50280623)

Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2021: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2020: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2019: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Keywordsタンキラーゼ / ポリ(ADP-リボシル)化 / がん / 分子標的治療
Outline of Research at the Start

タンキラーゼは、テロメアの伸長やWntシグナル伝達、細胞運動・浸潤といった様々ながん形質を支えるポリ(ADP-リボシル)化酵素である。我々が創製したタンキラーゼ阻害剤は、大腸がん細胞のWntシグナルを遮断し、マウス移植腫瘍の増殖を抑制する。本研究は、タンキラーゼ阻害剤の制がん効果を最大化する患者層別法もしくは併用療法を非臨床レベルで考案することを目的とする。具体的には、阻害剤の効果予測バイオマーカー、がん幹細胞に対する効果、合成致死因子、併用療法に適した薬剤を明らかにする。これらの少なくともいずれかを完遂することで、タンキラーゼ阻害剤の臨床開発の成功確率が向上すると期待される。

Outline of Final Research Achievements

Specific inhibitors for tankyrase poly(ADP-ribose) polymerases block the oncogenic Wnt signaling, which is often upregulated in colorectal and other cancers, and exert anticancer therapeutic effects. In this study, we aimed to optimize the therapeutic strategies with our newly developed tankyrase inhibitors, and revealed the predictive biomarkers, effects on cancer stem cells, synthetic lethal factors, and combination effects with cytotoxic anticancer drugs.

Academic Significance and Societal Importance of the Research Achievements

我が国では、高齢化・欧米食・肥満などの危険因子が蔓延し、年間5万人以上が大腸がんで死亡している。特に、治癒切除不能な再発・転移がんの根治的薬物療法は未確立であり、新薬の開発・提供が切望されている。今回得られた研究成果は、これまでに難攻不落とされてきたがん増殖シグナルを特異的に攻略する、革新的がん創薬の成功確率を向上させるとともに、がん個別化医療の発展につながるものである。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Annual Research Report
  • 2019 Annual Research Report
  • Research Products

    (53 results)

All 2022 2021 2020 2019 Other

All Int'l Joint Research (4 results) Journal Article (18 results) (of which Int'l Joint Research: 4 results,  Peer Reviewed: 18 results,  Open Access: 11 results) Presentation (24 results) (of which Int'l Joint Research: 3 results,  Invited: 13 results) Book (1 results) Remarks (2 results) Patent(Industrial Property Rights) (4 results) (of which Overseas: 1 results)

  • [Int'l Joint Research] Univ de Lyon/Institut Curie(フランス)

    • Related Report
      2021 Annual Research Report
  • [Int'l Joint Research] Univ Texas MD Anderson Cancer Center(米国)

    • Related Report
      2021 Annual Research Report
  • [Int'l Joint Research] Cancer Research Center of Lyon(フランス)

    • Related Report
      2020 Annual Research Report
  • [Int'l Joint Research] Universite Claude Bernard Lyon1(フランス)

    • Related Report
      2019 Annual Research Report
  • [Journal Article] Role of EMT in the DNA damage response, double‐strand break repair pathway choice and its implications in cancer treatment2022

    • Author(s)
      Moyret‐Lalle Caroline、Prodhomme Melanie K、Burlet Delphine、Kashiwagi Ayaka、Petrilli Virginie、Puisieux Alain、Seimiya Hiroyuki、Tissier Agnes
    • Journal Title

      Cancer Science

      Volume: in press Issue: 7 Pages: 2214-2223

    • DOI

      10.1111/cas.15389

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer2021

    • Author(s)
      Kenichi Miyata, Yoshinori Imai, Satoshi Hori, Mika Nishio, Tze Mun Loo, Ryo Okada, Liying Yang, Tomoyoshi Nakadai, et. al.
    • Journal Title

      Proc Natl Acad Sci U S A

      Volume: 118 Issue: 35

    • DOI

      10.1073/pnas.2025647118

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo2021

    • Author(s)
      Mashima Tetsuo、Wakatsuki Takeru、Kawata Naomi、Jang Myung-Kyu、Nagamori Akiko、Yoshida Haruka、Nakamura Kenichi、Migita Toshiro、Seimiya Hiroyuki、Yamaguchi Kensei
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 15125-15125

    • DOI

      10.1038/s41598-021-94584-9

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor2021

    • Author(s)
      Nishiya Naoyuki、Oku Yusuke、Ishikawa Chie、Fukuda Tsutomu、Dan Shingo、Mashima Tetsuo、Ushijima Masaru、Furukawa Yoko、Sasaki Yuka、Otsu Keishi、Sakyo Tomoko、Abe Masanori、Yonezawa Honami、Ishibashi Fumito、Matsuura Masaaki、Tomida Akihiro、Seimiya Hiroyuki、Yamori Takao、Iwao Masatomo、Uehara Yoshimasa
    • Journal Title

      Cancer Science

      Volume: - Issue: 5 Pages: 1963-1974

    • DOI

      10.1111/cas.14839

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Novel tankyrase inhibitors suppress TDP-43 aggregate formation2021

    • Author(s)
      Tanji Kunikazu、Mori Fumiaki、Shirai Fumiyuki、Fukami Takehiro、Seimiya Hiroyuki、Utsumi Jun、Kakita Akiyoshi、Wakabayashi Koichi
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 537 Pages: 85-92

    • DOI

      10.1016/j.bbrc.2020.12.037

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer2020

    • Author(s)
      Suenaga Mitsukuni、Mashima Tetsuo、Kawata Naomi、Wakatsuki Takeru、Dan Shingo、Seimiya Hiroyuki、Yamaguchi Kensei
    • Journal Title

      International Journal of Colorectal Disease

      Volume: 36 Issue: 1 Pages: 131-139

    • DOI

      10.1007/s00384-020-03748-y

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Crossroads of telomere biology and anticancer drug discovery2020

    • Author(s)
      Seimiya Hiroyuki
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 9 Pages: 3089-3099

    • DOI

      10.1111/cas.14540

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells2020

    • Author(s)
      Tomizawa Fumiya、Jang Myung-Kyu、Mashima Tetsuo、Seimiya Hiroyuki
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 527 Issue: 4 Pages: 1014-1020

    • DOI

      10.1016/j.bbrc.2020.05.024

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.2020

    • Author(s)
      Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, et al.
    • Journal Title

      J Med Chem

      Volume: 63 Issue: 8 Pages: 4183-4204

    • DOI

      10.1021/acs.jmedchem.0c00045

    • Related Report
      2020 Annual Research Report 2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.2020

    • Author(s)
      Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K, Seimiya H
    • Journal Title

      Cancer Sci

      Volume: 111 Issue: 3 Pages: 962-973

    • DOI

      10.1111/cas.14316

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.2020

    • Author(s)
      Jang MK, Mashima T, Seimiya H
    • Journal Title

      Mol Cancer Ther

      Volume: 19 Issue: 3 Pages: 765-776

    • DOI

      10.1158/1535-7163.mct-19-0668

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib2020

    • Author(s)
      Matsusaka Satoshi、Hanna Diana L.、Ning Yan、Yang Dongyun、Cao Shu、Berger Martin D.、Miyamoto Yuji、Suenaga Mitsukuni、Dan Shingo、Mashima Tetsuo、Seimiya Hiroyuki、Zhang Wu、Lenz Heinz‐Josef
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 2 Pages: 441-450

    • DOI

      10.1111/cas.14273

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Tankyrase promotes primary precursor miRNA processing to precursor miRNA.2020

    • Author(s)
      Mizutani A, Seimiya H.
    • Journal Title

      Biochem Biophys Res Commun

      Volume: 52 Issue: 4 Pages: 945-951

    • DOI

      10.1016/j.bbrc.2019.11.191

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] From the wings to the center stage of chromosomes.2019

    • Author(s)
      Okamoto K, Seimiya H.
    • Journal Title

      J Biol Chem

      Volume: 294 Issue: 47 Pages: 17723-17724

    • DOI

      10.1074/jbc.h119.011587

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.2019

    • Author(s)
      Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, Sano T, Yamaguchi K, Seimiya H
    • Journal Title

      Br J Cancer

      Volume: 121 Issue: 10 Pages: 846-856

    • DOI

      10.1038/s41416-019-0600-9

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.2019

    • Author(s)
      Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Mizutani A, et al.
    • Journal Title

      Journal of Medicinal Chemistry

      Volume: 62 Issue: 7 Pages: 3407-3427

    • DOI

      10.1021/acs.jmedchem.8b01888

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Meeting report of the 14th Japan Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine2019

    • Author(s)
      Sueoka Eisaburo、Watanabe Tatsuro、Mashima Tetsuo、Shirakami Yohei、Komori Atsumasa、Matsuo Keitaro、Yoshikawa Hiroshi Y.、Cho Kyung A、Park Tae Jun、Seimiya Hiroyuki、Kim Eung-Gook、Suganuma Masami、Chung Junho
    • Journal Title

      Journal of Cancer Research and Clinical Oncology

      Volume: 印刷中 Issue: 5 Pages: 1263-1271

    • DOI

      10.1007/s00432-019-02887-2

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study2019

    • Author(s)
      Suenaga Mitsukuni、Wakatsuki Takeru、Mashima Tetsuo、Ogura Mariko、Ichimura Takashi、Shinozaki Eiji、Nakayama Izuma、Osumi Hiroki、Ota Yumiko、Takahari Daisuke、Chin Keisho、Seimiya Hiroyuki、Yamaguchi Kensei
    • Journal Title

      Investigational New Drugs

      Volume: 印刷中 Issue: 1 Pages: 2567-2575

    • DOI

      10.1007/s10637-019-00749-9

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] ポリ(ADP-リボシル)化酵素タンキラーゼを標的としたがん創薬(アカデミア創薬の立場から)2022

    • Author(s)
      清宮啓之
    • Organizer
      日本がん分子標的治療学会・第5回産学連携に関する検討部会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] 患者腫瘍由来大腸がん細胞を用いたタンキラーゼ阻害剤感受性規定候補因子の評価2021

    • Author(s)
      陳 明じぇ, 馬島哲夫, 村松由起子, 清水裕貴, 長山 聡, 片山量平, 清宮啓之
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] テロメアから始まるがん創薬2021

    • Author(s)
      清宮啓之
    • Organizer
      広島大学大学院医系科学研究科「薬科学特論・薬科学特講」セミナー
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] 染色体の終わりから始まるがん創薬2021

    • Author(s)
      清宮啓之
    • Organizer
      日本遺伝学会公開市民講座
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] Telomere as the starting point for new cancer molecular medicine2020

    • Author(s)
      清宮啓之
    • Organizer
      広島大学大学院薬科学特論セミナー
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] テロメアから始まるがん創薬2020

    • Author(s)
      清宮啓之
    • Organizer
      第24回日本がん分子標的治療学会学術集会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 受容体型チロシンキナーゼ c-KIT による大腸がん幹細胞性の維持2020

    • Author(s)
      冨澤文弥, 張明奎, 馬島哲夫, 清宮啓之
    • Organizer
      第24回日本がん分子標的治療学会学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] shRNA スクリーニングによる大腸がん幹細胞の新規治療標的分子経路の探索2020

    • Author(s)
      森野峻, 馬島哲夫, 吉田稔, 清宮啓之
    • Organizer
      第24回日本がん分子標的治療学会学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] c-KITはCD44陽性大腸がん幹細胞の維持に寄与する2020

    • Author(s)
      冨澤文弥, 張明奎, 馬島哲夫, 清宮啓之
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] Telomere as the starting point of anticancer drug discovery2020

    • Author(s)
      Seimiya H.
    • Organizer
      LyonSE&N - ELyT Workshop 2020
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] 患者由来胃がん細胞の不均一性と薬剤抵抗性細胞の治療標的分子2020

    • Author(s)
      川上隆兵、馬島哲夫、川田直美、右田敏郎、熊谷厚志、佐野武、水沼信之、山口研成、清宮啓之
    • Organizer
      第1回日本癌学会若手の会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Tankyrase and G-quadruplex as molecular targets for cancer therapy2019

    • Author(s)
      Seimiya H.
    • Organizer
      第25回日本遺伝子細胞治療学会シンポジウム
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] Telomere as the starting point of anticancer drug discovery2019

    • Author(s)
      Seimiya H.
    • Organizer
      The 7th Symposium, RIKEN-Max Planck Joint Research Center
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] Crossroads of telomere biology and cancer drug discovery2019

    • Author(s)
      Seimiya H.
    • Organizer
      第78回日本癌学会学術総会コアシンポジウム
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] テロメアから始まるがん創薬2019

    • Author(s)
      清宮啓之
    • Organizer
      JSPS「日本におけるケミカルバイオロジーの新展開」 に関する産学協力研究委員会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] 分子プロファイリング支援活動のご紹介 ~小さな分子を起点とした生命科学研究のお手伝い2019

    • Author(s)
      清宮啓之
    • Organizer
      文部科学省新学術領域研究 学術研究支援基盤形成 先端モデル動物支援プラットフォーム 2019年度若手支援技術講習会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] Wnt/G4を標的としたがん創薬2019

    • Author(s)
      清宮啓之
    • Organizer
      広島大学大学院医系科学研究科セミナー
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] 染色体の末端から始まるがん創薬2019

    • Author(s)
      清宮啓之
    • Organizer
      徳島大学大学院医歯薬学研究部 呼吸器・膠原病内科学分野 開講48周年記念会 篠原 勉先生 特任教授就任祝賀会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] EGFR阻害剤による胃がん薬剤抵抗性CD44v発現細胞の増殖抑制とイリノテカンによる治療効果の増強2019

    • Author(s)
      馬島哲夫、岩崎里紗、川上隆兵、熊谷厚志、右田敏郎、佐野武、山口研成、清宮啓之
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] タンキラーゼ阻害剤によるAXIN2を介した大腸がん幹細胞のターゲティング2019

    • Author(s)
      張明奎、馬島哲夫、清宮啓之
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] EGFR阻害剤は胃がん薬剤抵抗性に寄与するCD44v発現細胞の増殖を抑制し、イリノテカンの治療効果を増強する2019

    • Author(s)
      馬島哲夫、岩崎里紗、川上隆兵、清宮啓之
    • Organizer
      第23回日本がん分子標的治療学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] タンキラーゼ阻害剤による大腸がん幹細胞の増殖抑制とその分子機序2019

    • Author(s)
      張明奎、馬島哲夫、清宮啓之
    • Organizer
      第23回日本がん分子標的治療学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] タンキラーゼ阻害剤による大腸がん幹細胞の増殖抑制とその分子メカニズム2019

    • Author(s)
      張明奎、馬島哲夫、清宮啓之
    • Organizer
      文部科学省新学術領域研究 学術研究支援基盤形成 先端モデル動物支援プラットフォーム 2019年度若手支援技術講習会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 幹細胞因子による大腸がん幹細胞の維持とその分子機序2019

    • Author(s)
      冨澤文弥、張明奎、馬島哲夫、清宮啓之
    • Organizer
      文部科学省新学術領域研究 学術研究支援基盤形成 先端モデル動物支援プラットフォーム 2019年度若手支援技術講習会
    • Related Report
      2019 Annual Research Report
  • [Book] 進化するがん創薬2019

    • Author(s)
      清宮啓之(編)
    • Total Pages
      344
    • Publisher
      化学同人
    • ISBN
      4759817336
    • Related Report
      2019 Annual Research Report
  • [Remarks] 研究室ホームページ

    • URL

      https://www.jfcr.or.jp/chemotherapy/department/molecular_biotherapy/index.html

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report
  • [Remarks] 研究室ホームページ

    • URL

      https://www.jfcr.or.jp/chemotherapy/department/molecular_biotherapy/

    • Related Report
      2019 Annual Research Report
  • [Patent(Industrial Property Rights)] 新規化合物又はその薬理的に許容される塩2019

    • Inventor(s)
      吉田 稔、清宮啓之、他11名
    • Industrial Property Rights Holder
      理化学研究所、がん研究会、株)ヤクルト本社
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Acquisition Date
      2021
    • Related Report
      2021 Annual Research Report
  • [Patent(Industrial Property Rights)] Novel compound or pharmaceutically acceptable salt thereof2019

    • Inventor(s)
      Yoshida M, Seimiya H et al.
    • Industrial Property Rights Holder
      理化学研究所、がん研究会、株)ヤクルト本社
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Acquisition Date
      2021
    • Related Report
      2021 Annual Research Report
    • Overseas
  • [Patent(Industrial Property Rights)] 抗VEGFR-2抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット2019

    • Inventor(s)
      馬島哲夫、若槻尊、清宮啓之、山口研成
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Acquisition Date
      2021
    • Related Report
      2021 Annual Research Report
  • [Patent(Industrial Property Rights)] マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー2019

    • Inventor(s)
      末永光邦、水沼信之、馬島哲夫、清宮啓之
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Acquisition Date
      2021
    • Related Report
      2021 Annual Research Report

URL: 

Published: 2019-04-18   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi